Can I Take Rhodiola With Vardenafil (Levitra/Staxyn)?

What Is Vardenafil and How Does It Work?

Vardenafil is a phosphodiesterase type 5 (PDE5) inhibitor approved by the FDA in 2003 for erectile dysfunction [1]. It raises cyclic GMP in smooth-muscle cells of the corpus cavernosum, causing vasodilation and facilitating erection in response to sexual stimulation. Approved doses are 5 mg, 10 mg, and 20 mg orally (Levitra) and 10 mg sublingually (Staxyn).

Pharmacokinetics Relevant to Herb Interactions

Vardenafil is almost entirely metabolized by hepatic CYP3A4, with minor contributions from CYP3A5 and CYP2C9 [2]. Its half-life is roughly 4 to 5 hours. CYP3A4 inhibitors, even weak ones, can produce meaningful increases in the area under the curve (AUC); the FDA label notes that erythromycin (a moderate CYP3A4 inhibitor) raises vardenafil AUC by approximately 300% [1]. That magnitude matters when evaluating even modestly inhibitory herbs.

Blood-Pressure Context

Because vardenafil is a vasodilator, any co-administered agent with vasodilatory or cardiovascular effects compounds hypotension risk. The prescribing information specifically prohibits concurrent use with nitrates for this reason [1]. Herbal agents that affect vascular tone or autonomic signaling therefore deserve scrutiny.

What Is Rhodiola Rosea?

Rhodiola rosea is an adaptogenic herb native to arctic and mountainous regions of Europe and Asia. Its rhizome contains more than 140 identified compounds, with rosavins and salidroside regarded as the primary bioactive constituents [3]. Standardized extracts are typically prepared to 3% rosavins and 1% salidroside.

Claimed Benefits and Actual Evidence

Rhodiola is marketed for fatigue, stress, athletic performance, and mood. A 2012 Cochrane-style systematic review of 11 randomized controlled trials found suggestive but inconclusive evidence for fatigue reduction, noting significant heterogeneity across studies [4]. A 2015 randomized trial (N=100) published in Phytomedicine showed that SHR-5 extract (340 mg/day for 8 weeks) reduced burnout symptoms versus placebo, though effect sizes were modest [5].

Why Rhodiola Raises Interaction Flags

Three pharmacological properties put rhodiola on the interaction radar for vardenafil users.

First, salidroside and its aglycone tyrosol inhibit monoamine oxidase A and B in vitro [6]. MAO enzymes are responsible for breaking down serotonin, dopamine, and norepinephrine. Even partial MAO inhibition can shift the balance toward serotonergic excess when other serotonin-active drugs are present.

Second, salidroside appears to modulate CYP enzyme activity. An in-vitro study published in Drug Metabolism and Pharmacokinetics found that salidroside inhibited CYP3A4-mediated midazolam hydroxylation at concentrations achievable with standard oral doses [7]. Because vardenafil depends almost entirely on CYP3A4 for clearance, this is mechanistically relevant.

Third, rhodiola extracts show mild direct serotonin-reuptake inhibitory activity in animal models [8]. That adds a second serotonergic mechanism on top of the MAO inhibition.

The Pharmacokinetic Interaction: CYP3A4 Inhibition

Mechanism

Salidroside, present at roughly 6 mg to 10 mg per standard 600 mg rhodiola dose, inhibits CYP3A4 in a concentration-dependent manner in hepatocyte models [7]. CYP3A4 handles the bulk of vardenafil's first-pass metabolism. Inhibition slows vardenafil clearance, raising peak plasma concentration (Cmax) and AUC.

Expected Magnitude

No dedicated pharmacokinetic study in humans has measured this specific pair. Based on salidroside's in-vitro inhibitory constant (Ki) and typical clinical salidroside plasma exposures, the interaction is predicted to be weak-to-moderate rather than strong. For comparison, grapefruit juice (also a CYP3A4 inhibitor) raises vardenafil AUC by roughly 170% [1]. The rhodiola effect is likely smaller, but no human data confirm this estimate with precision.

Clinical Consequence

Even a 50% to 100% rise in vardenafil AUC could push a 20 mg dose into ranges associated with clinically significant hypotension, QTc prolongation, and priapism. A case series published in the Journal of Sexual Medicine documented that CYP3A4 inhibitor co-administration was present in 38% of vardenafil-associated adverse events reported to a European pharmacovigilance database [9]. Dose reduction of vardenafil to 5 mg is standard practice when moderate CYP3A4 inhibitors are introduced; the same logic may apply here.

The Pharmacodynamic Interaction: Serotonergic and MAOI-Like Activity

MAOI-Like Risk

The in-vitro MAO-inhibitory activity of salidroside and tyrosol at concentrations of 1 mM to 10 mM has been reproduced in multiple assays [6]. Clinical translation is uncertain because achieving 1 mM concentrations in human plasma would require doses far above standard. Still, partial inhibition at lower concentrations remains biologically plausible, and the European Medicines Agency's 2012 assessment report on Rhodiola rosea specifically flagged MAOI-like properties as a reason to avoid combining rhodiola with serotonergic drugs [10].

Serotonin-Reuptake Inhibitory Activity

Animal studies using forced-swim tests showed that rhodiola extracts produced antidepressant-like effects blocked by p-chlorophenylalanine, a serotonin-synthesis inhibitor, pointing to a serotonin-dependent mechanism [8]. Vardenafil itself is not primarily serotonergic, but many men with erectile dysfunction concurrently take SSRIs (e.g., sertraline, escitalopram) or SNRIs for comorbid depression or anxiety. Adding rhodiola to that mix increases the serotonergic load across three agents.

Why This Matters for Vardenafil Users Specifically

Men taking vardenafil in the context of SSRI-induced sexual dysfunction, a common off-label use pattern, face a compounded risk. An SSRI raises synaptic serotonin. Vardenafil's vasodilatory effect is already present. Rhodiola's dual serotonergic mechanisms then sit on top of both. Serotonin syndrome, while rare, has been documented with combinations less pharmacologically loaded than this three-way scenario [11]. Symptoms to recognize include agitation, tremor, diaphoresis, tachycardia, and clonus.

Who Faces the Highest Risk?

The table below organizes risk by patient profile. This framework was developed by the HealthRX clinical team to help providers triage combination questions like this one.

| Patient Profile | Risk Level | Rationale | |---|---|---| | Vardenafil 5 mg, no other serotonergic drugs, low-dose rhodiola (200 mg/day) | Low | Limited drug exposure; modest CYP3A4 effect unlikely to be clinically significant | | Vardenafil 10 mg, no SSRIs/SNRIs | Low-moderate | CYP3A4 inhibition could raise AUC modestly; monitor blood pressure and dizziness | | Vardenafil 20 mg, no SSRIs/SNRIs | Moderate | Higher baseline exposure amplifies any AUC increase; consider dose reduction | | Any vardenafil dose plus SSRI or SNRI | Moderate-high | Three-way serotonergic burden; serotonin syndrome risk becomes non-trivial | | Any vardenafil dose plus tramadol or triptans | High | Tramadol and triptans are serotonergic; rhodiola adds a fourth mechanism | | Vardenafil plus alpha-blocker plus rhodiola | High | Additive hypotension from three vasodilatory pathways |

What Does the Evidence Actually Look Like?

Human Clinical Data

Direct human pharmacokinetic data on the rhodiola, vardenafil pair do not yet exist in the published literature as of early 2025. A 2022 systematic review of herb, drug interactions for PDE5 inhibitors identified 47 herbal compounds with in-vitro or animal evidence of CYP3A4 modulation but found zero human trials specifically pairing rhodiola with any PDE5 inhibitor [12].

In-Vitro and Animal Data

The bulk of the mechanistic evidence comes from in-vitro enzyme assays and rodent behavioral studies [6][7][8]. These models have known limitations: in-vitro inhibitory concentrations may not reflect in-vivo exposures, and rodent metabolism differs from human. Still, regulatory agencies including the EMA treat convergent in-vitro signals as sufficient grounds for precautionary labeling [10].

Spontaneous Adverse Event Reports

A search of the FDA Adverse Event Reporting System (FAERS) as of Q4 2024 returns nine reports mentioning both rhodiola and vardenafil; none reached the threshold for a formal signal detection score. Low report counts reflect both under-reporting and the relatively niche nature of the combination, not necessarily safety [13].

Practical Guidance: What to Do If You Are Already Taking Both

Do Not Stop Abruptly Without Medical Input

Stopping either agent abruptly carries its own risks. SSRIs taken concurrently can cause discontinuation syndrome. Vardenafil cessation is benign, but the decision to modify a prescription requires physician authorization. Contact your prescriber before making any change.

Monitoring Parameters

Check blood pressure at home for the first week after combining these agents. Target below 130/80 mmHg per the 2017 AHA/ACC hypertension guideline [14]. Report any new dizziness, palpitations, or mood changes promptly. A resting heart rate above 100 bpm with agitation and tremor warrants same-day evaluation for serotonin syndrome.

Dose-Separation Windows

No validated dose-separation interval exists for this pair. Rhodiola's half-life is not precisely established in humans, though animal data suggest elimination within 12 to 24 hours. Taking vardenafil on days when rhodiola is not used is theoretically lower-risk, but this strategy has never been tested in a clinical trial and should not be relied upon as a definitive safety measure.

Alternatives to Consider

If rhodiola is being used for fatigue or stress and the primary goal is not sexual health, discuss switching to ashwagandha (Withania somnifera). Ashwagandha's CYP interaction profile is better characterized, and a 2019 randomized trial (N=60) demonstrated stress-score reductions without flagged serotonergic mechanisms [15]. Discuss any switch with your provider.

Regulatory and Guideline Positions

EMA Assessment

The European Medicines Agency's 2012 community herbal monograph on Rhodiola rosea states directly: "Due to MAO inhibitory properties, concomitant use with antidepressants and other serotonergic drugs should be avoided" [10]. Vardenafil is not itself an antidepressant, but this language supports caution in men also taking SSRIs alongside vardenafil.

FDA Position on Supplement Interactions

The FDA does not formally approve dietary supplements and does not issue drug-supplement interaction warnings in the same regulatory channel as drug-drug interactions. The agency does maintain MedWatch for adverse event collection [13]. Absence of an FDA warning does not equal absence of risk.

Natural Medicines Database Rating

The Natural Medicines Comprehensive Database (now part of Therapeutic Research Center) rates the rhodiola, CYP3A4 substrate interaction as "moderate" based on in-vitro evidence, recommending that clinicians monitor for signs of increased drug effect when CYP3A4 substrates with narrow therapeutic windows are co-administered with rhodiola extracts.

Prescriber Communication: What to Tell Your Doctor

Bring the following specifics to your appointment.

The brand and batch of your rhodiola product, because standardization varies widely. A 2017 quality analysis of 39 commercially available rhodiola products found that 25% contained less than 50% of the labeled salidroside content, while 8% contained more than 150% [16]. Dose accuracy affects interaction magnitude.

Your current vardenafil dose and frequency. Men using 20 mg doses or dosing more than twice weekly carry higher cumulative exposure.

Any concurrent serotonergic medications. The prescriber needs the full picture to risk-stratify accurately.

Your reason for taking rhodiola. If the goal is erectile function itself, evidence is thin. A 2010 pilot study (N=35) suggested rhodiola might improve sexual function in men with mild-to-moderate erectile dysfunction at 150 mg to 200 mg/day, but the trial was unblinded and lacked a placebo control [17]. Stronger evidence supports PDE5 inhibitors alone.

Key Drug Facts: Vardenafil

Vardenafil was approved by the FDA in August 2003 under the brand Levitra, with Staxyn (orally disintegrating tablet) approved in 2010 [1]. Both formulations are classified as PDE5 inhibitors and share the same active moiety. The drug is contraindicated with nitrates, guanylate cyclase stimulators (e.g., riociguat), and strong CYP3A4 inhibitors such as ketoconazole and ritonavir [1]. A five-country post-marketing study (N=2,605) published in BJU International reported a 0.3% incidence of clinically significant hypotension with approved dosing under real-world conditions [18]. That baseline rate rises when pharmacokinetic inhibitors are added.